With notable implications in pharmaceutical research, particularly as angiotensin-converting enzyme (ACE) and aminopeptidase inhibitors, microginins offer a promising avenue for the development of innovative therapeutic modalities in diverse medical fields, ranging from treatments for cardiovascular disorders to oncological interventions. Here, CPQ is linked to cardiovascular disorder.